AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support. In addition, the company provides thrombolytic catheters to deliver thrombolytic agents; angiographic products and accessories for use in during peripheral vascular interventional procedures; drainage products, which drain abscesses and other fluid pockets; and micro access sets. Further, it offers peripherally inserted central catheters; ports that are implantable devices for the central venous administration; and dialysis products. Additionally, the company provides microwave ablation products; radiofrequency ablation products for ablating solid cancerous or benign tumors; and NanoKnife ablation systems for the surgical ablation of soft tissues. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, and interventional and surgical oncologists directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ANGO
CUSIP03475V10
Phone518-795-1400
Debt
Debt-to-Equity Ratio0.16
Current Ratio2.93
Quick Ratio2.08
Price-To-Earnings
Trailing P/E Ratio28.28
Forward P/E Ratio24.34
P/E Growth1.64
Sales & Book Value
Annual Sales$344.29 million
Price / Sales2.24
Cash Flow$1.3698 per share
Price / Cash15.28
Book Value$14.74 per share
Price / Book1.42
Profitability
EPS (Most Recent Fiscal Year)$0.74
Net Income$16.33 million
Net Margins4.74%
Return on Equity5.21%
Return on Assets3.94%
Miscellaneous
Employees1,250
Outstanding Shares36,810,000
Market Cap$775.84
AngioDynamics (NASDAQ:ANGO) Frequently Asked Questions
What is AngioDynamics' stock symbol?
AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."
How were AngioDynamics' earnings last quarter?
AngioDynamics, Inc. (NASDAQ:ANGO) issued its quarterly earnings data on Wednesday, July, 11th. The medical instruments supplier reported $0.20 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.21 by $0.01. The medical instruments supplier earned $88.30 million during the quarter, compared to the consensus estimate of $89.02 million. AngioDynamics had a net margin of 4.74% and a return on equity of 5.21%. The company's revenue was up 1.6% on a year-over-year basis. View AngioDynamics' Earnings History.
When is AngioDynamics' next earnings date?
What guidance has AngioDynamics issued on next quarter's earnings?
AngioDynamics issued an update on its FY19 earnings guidance on Wednesday, July, 11th. The company provided earnings per share (EPS) guidance of $0.82-0.86 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.91. The company issued revenue guidance of $344-349 million, compared to the consensus revenue estimate of $347.79 million.
What price target have analysts set for ANGO?
6 equities research analysts have issued 12 month price targets for AngioDynamics' stock. Their forecasts range from $16.00 to $20.00. On average, they expect AngioDynamics' stock price to reach $17.4433 in the next twelve months. This suggests that the stock has a possible downside of 16.7%. View Analyst Ratings for AngioDynamics.
What is the consensus analysts' recommendation for AngioDynamics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
Who are some of AngioDynamics' key competitors?
Some companies that are related to AngioDynamics include Merit Medical Systems (MMSI), NuVasive (NUVA), Irhythm Technologies (IRTC), Nevro (NVRO), Mazor Robotics (MZOR), Luminex (LMNX), Glaukos (GKOS), Tandem Diabetes Care (TNDM), Cardiovascular Systems (CSII), Atrion (ATRI), Orthofix International (OFIX), Cryolife (CRY), Intersect ENT (XENT), AtriCure (ATRC) and OraSure Technologies (OSUR).
Who are AngioDynamics' key executives?
AngioDynamics' management team includes the folowing people:
- Mr. James C. Clemmer, Pres, CEO & Director (Age 54)
- Mr. Michael C. Greiner, Exec. VP, CFO & Principal Accounting Officer (Age 45)
- Mr. Stephen A. Trowbridge, Sr. VP, Gen. Counsel & Assistant Sec. (Age 44)
- Mr. Chad T. Campbell, Sr. VP & Gen. Mang. of Global Vascular Access (Age 47)
- Mr. Robert A. Simpson, Sr. VP Peripheral Vascular (Age 46)
Has AngioDynamics been receiving favorable news coverage?
News stories about ANGO stock have been trending somewhat positive recently, Accern reports. Accern scores the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. AngioDynamics earned a media sentiment score of 0.20 on Accern's scale. They also assigned media coverage about the medical instruments supplier an impact score of 44.76 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are AngioDynamics' major shareholders?
AngioDynamics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Fenimore Asset Management Inc. (1.54%), Capital One National Association (0.36%), Bank of Montreal Can (0.15%), Boston Advisors LLC (0.12%), First National Bank of Omaha (0.09%) and Campbell & CO Investment Adviser LLC (0.06%). Company insiders that own AngioDynamics stock include Avista Capital Partners Gp, Ll, David F Burgstahler, James C Clemmer and Jan Stern Reed. View Institutional Ownership Trends for AngioDynamics.
Which major investors are selling AngioDynamics stock?
Which major investors are buying AngioDynamics stock?
ANGO stock was acquired by a variety of institutional investors in the last quarter, including Capital One National Association, Boston Advisors LLC, First National Bank of Omaha, Campbell & CO Investment Adviser LLC and Port Capital LLC. Company insiders that have bought AngioDynamics stock in the last two years include James C Clemmer and Jan Stern Reed. View Insider Buying and Selling for AngioDynamics.
How do I buy shares of AngioDynamics?
Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AngioDynamics' stock price today?
One share of ANGO stock can currently be purchased for approximately $20.93.
How big of a company is AngioDynamics?
AngioDynamics has a market capitalization of $775.84 million and generates $344.29 million in revenue each year. The medical instruments supplier earns $16.33 million in net income (profit) each year or $0.74 on an earnings per share basis. AngioDynamics employs 1,250 workers across the globe.
How can I contact AngioDynamics?
AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected]
MarketBeat Community Rating for AngioDynamics (NASDAQ ANGO)
MarketBeat's community ratings are surveys of what our community members think about AngioDynamics and other stocks. Vote "Outperform" if you believe ANGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANGO will underperform the S&P 500 over the long term. You may vote once every thirty days.
